The aim of this study was to investigate the effect of long-term intake of Tartary buckwheat tea on the pharmacokinetics (PK) of eplerenone in rats. A validated highperformance liquid chromatography-mass spectrometry (HPLC-MS) method was established to determine the eplerenone in plasma, and the portal vein absorption model was applied to conduct the pharmacokinetic study. Two groups of animalsdbuckwheat tea group and control groupdwere involved in this study. Plasma samples were obtained at different time points after administration, and were separated on Shimadzu HPLC-MS 2020 instruments. The method showed good linearity (r Z 0.9988) over a wide dynamic range (0.20e50 mg/mL). Within-and between-batch precisions ranged from 2.13% to 7.90%. The extraction recovery rates ranged from 91.96% to 94.96%. The data showed that in the Tartarian buckwheat group the area under the curve and maximum concentration of eplerenone were reduced compared with those of the blank group (p < 0.01), but the time to reach peak concentrations of eplerenone (p < 0.01) was prolonged. The results suggested that long-term consumption of Tartary buckwheat tea might induce the activities of the hepatic drug metabolizing enzyme, which can accelerate the metabolism of eplerenone. According to the results, the dosage of eplerenone should be adjusted in hypertension treatment trials when administered with Tartary buckwheat or Tartary buckwheatcontaining dietary supplements to avoid potential drug interactions.
Introduction
Tartary buckwheat, a dried mature seed of Fagopyrum genera in the Polygonaceae family, is mainly produced in southwestern and northern China. It is rich in flavonoids, oleic acid, vitamins, niacin, and dietary fiber [1, 2] . The amount of flavonoids in Tartary buckwheat is 10e100 times higher than that of other buckwheat species, in which rutin makes up 70e90%.
Previous studies reported that flavonoids in Tartary buckwheat have hypoglycemic, serum lipid-lowering, and antihypertensive effects [3, 4] . As a result, Tartary buckwheat tea has become a popular healthy drink in recent years. It is reported that the main bioactive ingredients of Tartary buckwheatdrutin, quercetin, kaempferol, and naringin [5, 6] , are inhibitors or activators of CYP3A4, CYP1A1, and CYP1A2 of the cytochrome P450 (CYP450) system [7e10] . Eplerenone, a type of a selective aldosterone receptor blocker, is mainly metabolized by CYP3A4 and has been used for the treatment of hypertension for a long time [11, 12] . In clinics, rutin and quercetin frequently result in the emergence of drugedrug interactions by affecting the activities of drug-metabolizing enzymes [13e15] . If eplerenone is simultaneously coadministered with buckwheat tea to patients, the bioavailability and metabolism of eplerenone can be affected.
The purpose of this study is to investigate whether the long-term administration of buckwheat tea could affect the pharmacokinetic (PK) profile of eplerenone in rats. A validated high-performance liquid chromatography-mass spectrometry (HPLC-MS) method was established to determine the eplerenone in plasma, and the portal vein absorption model was applied to conduct the pharmacokinetic study. Two groups of animals, the buckwheat tea group and the control group, were used in the study. The result of this study was expected to provide an experimental foundation for the coadministration of eplerenone and buckwheat tea in the clinical treatment of hypertension.
Materials and methods

Chemicals and reagents
Tartarian buckwheat tea was purchased from Zhengzhong Food Co., Ltd (Xichang, China). Eplerenone, rutin, and quercetin, were purchased from the National Institutes for Food and Drug Control (Beijing, China). Astragaloside (IS) was purchased from Sigma Chemical Co. (St. Louis, MO, USA). b-Cyclodextrin, sodium phosphate buffer solution, and sodium chloride were purchased from Beijing Chemical Corporation (Beijing, China). HPLC-grade acetonitrile and methanol were obtained from Fisher Scientific (Iowa, USA). HPLC-grade formic acid was purchased from Kelong Chemical Industry (Chengdu, China), and ultrapure water was produced using a Millipore Milli-Q system (Millipore, Billerica, MA, USA). All the other reagents used were of reagent grade. The chemical structures of eplerenone and IS are shown in Figure 1 .
Animal
Male SpragueeDawley rats of specified pathogen free (SPF) grade were obtained from the Laboratory Animal Center of Sichuan Health Science Academy (Certificate No. SCXK 2004-6) . The rats were housed in an animal room with air conditioning (22e24 C) and free access to food and water. Treatment of all animals was in accordance with the National Institutes of Health Guide to the Care and Use of Laboratory Animals. The experiments were carried out under the approval of Experiment Administration Committee of Sichuan Health Science Academy.
Drug administration
The Tartarian buckwheat water solution for the experiment was prepared by boiling 17.8 g Tartarian buckwheat with 10 times of water for 5 minutes, followed by another 10minute boiling cycle with 5 times of water. The solution was combined and concentrated to 100 mL. After centrifugation at 13,500g for 5 minutes, the clear supernatant was filtered by 0.22-mm (pore size) membrane. The filtrate was considered Tartarian buckwheat test solution, with a concentration of 0.178 g/mL.
We also prepared a lower concentration of Tartarian buckwheat solution as a substitute for the drinking water of the animals. Specifically, 5.34 g Tartarian buckwheat was treated under two boiling cycles (40 times of water for 5 minutes and 45 times of water for 10 minutes). The combined solution was concentrated to 300 mL, with a concentration of 0.0178 g/mL.
Eplerenone physic liquor was prepared by dissolving 1 g of eplerenone in 100 mL of a mixed solution that consisted of 15% b-cyclodextrin, 0.07 mol/L sodium phosphate buffer solution (pH 7.4), and 0.5% sodium chloride.
Animal experiment and drug administration
After 1 week of acclimatization, 20 male SpragueeDawley rats (200e220 g) were randomly divided into the blank group and the Tartarian buckwheat group (10 rats in each group). Rats in the Tartarian buckwheat group were administered with Tartarian buckwheat water solution [1.78 g/kg, intragastric gavage (i.g.)] twice a day for 29 days. During these days, the lower concentration buckwheat solution substituted for the animals' drinking water. Rats were fasted for 12 hours prior to the experiment with drinking water supply as usual. Rats in the two groups were orally administered with eplerenone solution (100 mg/kg). The blood samples (0.2 mL) were obtained 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 6 hours, 8 hours, and 10 hours after the administration. The blood samples were preserved in a 37 C water bath for 20 minutes and then centrifuged at 3500 rpm for 10 minutes. The upper phase was transferred and preserved in a refrigerator (at À80 C) for future analysis.
Sample preparation
Rat plasma sample (20 mL) was transferred into 4-mL tubes prior to adding 20 mL IS. The mixture was vortexed for 10 seconds, and acetonitrile (2 mL) was then added to form an emulsion. The emulsion was vortexed for 3 minutes followed by centrifugation at 4000 rpm for 8 minutes. The upper organic phase was transferred into a new tube and centrifuged at 13,400 rpm for 3 minutes. The upper phase was transferred into an injection vial for HPLC-electrospray ionization (ESI)-MS analysis.
Quantitative analysis of Tartarian buckwheat water solution
Quantitative analysis was carried out on a 1260 Agilent HPLC system. Chromatography separation was performed on an Agilent Zorbax SB-C18 guard column (12.5 mm Â 4.6 mm inner diameter (i.d.), 5 mm). The multi wavelength detector (MWD) was operated at 375 nm, and the column temperature was set at 30 o C. Then, 20 mL Tartarian buckwheat water solution was eluted at a flow rate of 0.8 mL/min, using a mobile phase of 0.2% (v/v) phosphoric acid in water and acetonitrile. The proportion of acetonitrile in the mobile phase was optimized as follows: 0e8 minutes, 28%; 8e18 minutes, 50%; 18e30 minutes, 100%; 30e35 minutes, 100%; 35e38 minutes, 28%.
Quantitative and qualitative analysis of plasma samples
Chromatography separation was performed on an Agilent Poroshell 120 EC-C18 column (2.7 mm, 4.6 Â 100 mm) using a Shimadzu HPLC-MS 2020 system (Shimadzu MS Technologies, Japan), which was equipped with a binary solvent delivery system, an online vacuum degasser, an autosampler, an ultraviolet detector, a column oven, and labsolution 5.5 chromatographic work station. The column was maintained at 30 o C and eluted at a flow rate of 1.0 mL/min, using a mobile phase consisting of 10 mmol/L ammonium acetate in water and acetonitrile. The proportion of acetonitrile in the mobile phase was 70%.
Mass spectrometry was carried out on a Shimadzu 2020 mass spectrometer with an ESI interface operating in positive ion mode.
Stock solutions, calibration standard, and quality control samples
Stock solutions of rutin and quercetin were prepared at 350 mg/mL in methanol. A stock solution of eplerenone was prepared at 500 mg/mL in methanol. The IS solution was prepared at 53.10 mg/mL in methanol. Calibration curves were prepared by spiking 20 mL of an appropriate working solution into 1.5-mL tubes, evaporating to dryness under a nitrogen stream, and spiking with 100 mL of blank rat plasma. The effective concentrations were 0.20, 0.50, 2, 5, 10, 20, and 500 mg/mL of eplerenone. Quality control (QC) samples were prepared in pool as a single batch for each concentration at concentrations of 0.20, 10, and 50 mg/L for eplerenone, and then divided into aliquots and stored in the freezer at À20 C. The IS working solution of 5.31 mg/mL was diluted from stock solution as needed. The rat plasma sample (calibration standards and QCs) were treated following the sample processing procedure.
Data analysis
Kinetica 5.0.11 software (Thermo Electron Corporation, USA) was used to fit the model. Maple15 software (Maple Corporation, Japan) was used to perform statistical analysis. One-way analysis of variance was carried out to compare data interclass. The least significant difference (LSD) test was appropriate to equal variance and Tamhane's T2 test was appropriate to heterogeneity of variance. A p value < 0.05 was considered significant.
Results
Method validation
The method for determination of eplerenone in rat plasma by HPLC-MS was validated to meet the guidelines of the Eplerenone Astragaloside International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use and acceptance criteria as the guidance from the Food and Drug Administration.
Specificity
IS was chosen as the internal standard for eplerenone quantitation because of the similar chromatographic behavior with eplerenone. The typical HPLC chromatograms of blank plasma spiked with eplerenone/IS, and a sample obtained from an experimental rat at 1.5 hours after an oral administration of eplerenone solution (100 mg/kg) are shown in Figure 2 . Under the assay conditions, eplerenone and IS were completely separated, and no endogenous substances interfered with eplerenone and IS in the plasma samples prepared from six different rats ( Figure 2 ).
Calibration curves and limit of detection
The standard curve, established by plotting peak area ratios (y) of eplerenone to IS against analyte concentrations (x), exhibited good linearity over the concentration range of 0.20e50 mg/mL. The regression equation for eplerenone was y Z 1.5006x À 0.0850. The lower limit of quantitation (LLOQ) for eplerenone was defined as 0.10 mg/mL based on Signal/Noise (S/N) Z 10, and the limit of detection was estimated as 0.02 mg/mL based on S/N Z 3. According to our previous analysis, 0.20 mg/mL eplerenone is suitable for the pharmacokinetic study and was selected as the lowest concentration on the calibration curves.
Precision and accuracy
The intraday and interday precision and accuracy for eplerenone were evaluated by assaying three QC levels (0.20, 10, and 50 mg/mL) on 6 consecutive days, and five samples were prepared for every level. The results are presented in Table 1 . For each QC level of eplerenone, the intraday precision was lower than 7.51%, and the accuracy was between 95.16% and 101.67%; the interday precision was lower than 7.90%, and the accuracy was between 96.67% and 97.83%. These data suggested that the method was accurate and precise for the analysis of eplerenone in rat plasma samples.
Recovery
The extraction recovery of eplerenone was determined at three QC levels. Recovery was calculated by comparing the analyte/IS peak area ratios of each analyte in plasma samples to those in the matrices by spiking the extracted analyte-free plasma samples prior to chromatography. Recovery was calculated using the following formula: recovery (%) Z concentration found/concentration spiked Â 100%. The recovery rates of eplerenone were 94.96 AE 6.65%, 91.96 AE 1.96%, and 93.29 AE 4.21% (n Z 3) at concentrations of 0.20, 10, and 50 mg/mL, respectively ( Table 2 ).
Stability
Stability was evaluated at three QC levels. The stability of standard solutions was tested at room temperature for 2 hours and upon refrigeration (4 C) for 30 days. The stability of analytes was examined by keeping eplerenone QC samples in the autosampler tray for 24 hours and in a freezer at À20 C for 30 days; the freezeethaw stability was obtained over three freezeethaw cycles, by thawing at room temperature for 2e3 hours and then refreezing at À20 C for 12e24 hours. For each concentration and each storage condition, six replicates were analyzed in one analytical batch. The concentration of analytes after each storage period was related to the initial concentration, which was determined when the samples were originally prepared and processed. Results are shown in Table 3 . The results of the stability tests indicated that the standard solutions are stable at room temperature for 2 hours (relative standard deviation (RSD) < 7.98%) and upon refrigeration (4 C) for 30 days (RSD < 7.90%). The analytes were stable in plasma samples for 24 hours (RSD < 7.18%) and in a freezer at À20 C for 30 days (RSD < 6.04%). The freezeethaw stability was obtained over three freezeethaw cycles (RSD < 5.78%).
Quantitative analysis of Tartarian buckwheat water solution
Quantitative analyses of rutin, isoquercitrin, quercetin, and kaempferol were carried out. The typical chromatograms of the Tartarian buckwheat water solution are shown in Figure 3 . The content of rutin, isoquercitrin, quercetin, and kaempferol was determined to be 9.05, 0.25, 0.71, and 0.04 mg/g, respectively.
Pharmacokinetic and PK parameters analysis
The method was applied to the quantification of eplerenone in rat plasma samples after i.g. administration. The mean concentrationetime curves of eplerenone after the administration of 100 mg/kg (i.g.) to the control and buckwheat tea groups are shown in Figure 4 ; the main pharmacokinetic parameters were calculated and are shown in Table 4 .
One-way analysis of variance was carried out for statistical analysis to compare the data of the two groups. According to the data shown in Table 4 , the maximal concentration of eplerenone (C max ) was observed at 33.36 AE 3.35 mg/mL in the buckwheat tea group and 43.62 AE 3.24 mg/mL in the control group. The time to reach peak concentrations of eplerenone (T max ) was observed at 1.00 AE 0.00 hours in the buckwheat tea group and 0.50 AE 0.00 hour in the control group. The area under the curve of eplerenone (AUC last ) was 50.31 AE 4.28 mg h/mL in the buckwheat tea group and 58.79 AE 8.03 mg h/mL in the control group. The mean retention time for eplerenone was 2.01 AE 0.07 hours in the buckwheat tea group and 2.17 AE 0.13 hours in the control group. 
Discussion
Studies have demonstrated that eplerenone was well absorbed and rapidly metabolized after oral administration [16] . In our work, the value of T max was consistent with that found in some previous studies, but the C max of eplerenone was much higher. It is most likely that eplerenone was dissolved in the sulfobutyl-b-cyclodextrin solution, which can be a good package for the drug molecule, forming a noncovalent complexes and enhancing the stability and water solubility of eplerenone.
CYP450 is considered to be the most important drugmetabolizing enzyme system in the body. Various studies have demonstrated that quercetin is an inhibitor of CYP3A4 and that it inhibits CYP3A4 enzyme activity in a concentration-dependent manner [8, 14] . However, some studies suggest that different components of flavonoids may exert different effects on the hepatic microsomal monooxygenase system according to the route and the duration of administration [17] . An earlier study showed that there was no significant difference in Phase I or Phase II enzyme activities when quercetin was given for 14 days at a concentration of 1%. In contrast, the liver weight, protein content of microsomal and cytoplasmic, and activity of cytochrome P450 were substantially increased when 0.25% flavone was given [18] .
It has been known that 6b-hydroxy eplerenone and 21hydroxy eplerenone are the major metabolites in vitro in both humans and dogs, and that the metabolism of eplerenone was primarily mediated by CYP3A4 in humans and CYP3A12 in dogs [11] . However, 6b-OH eplerenone was the major metabolite in rats, and eplerenone metabolism to 6b-OH eplerenone (EP) was mediated primarily by CYP3A [12] . The results from our study clearly demonstrated that long-term coadministration of Tartary buckwheat tea can significantly reduce the C max and AUC, extend the T max , and accelerate the elimination of eplerenone. The reduced bioavailability of eplerenone as a result of its coadministration with Tartary buckwheat suggested that Tartary buckwheat may promote the first-pass metabolism of eplerenone. It is predicted that long-term consumption of Tartary buckwheat tea might induce the activities of the hepatic drug-metabolizing enzyme. The results of the current study strongly indicate that the dosage of eplerenone should be adjusted in hypertension treatment trials when administered with Tartary buckwheat or Tartary buckwheat-containing dietary supplements to avoid potential drug interactions.
